The crosstalk effect of cancer stem cells in the progression of pediatric medulloblastoma through signaling expression of CD133, CD44, and OCT4 with and without Wnt-β-catenin activation

被引:0
作者
Kurdi, Maher [1 ]
Alkhotani, Alaa [2 ]
Fadul, Motaz [1 ]
Alghefari, Huda [1 ]
Tayyib, Awab T. [3 ]
Alsharif, Thamer [4 ]
Almansouri, Majid [5 ]
Maghrabi, Yazid [6 ]
Alkhayyat, Shadi [7 ]
Alsinani, Taghreed [8 ]
Bamaga, Ahmed K. [9 ]
Baeesa, Saleh [6 ]
机构
[1] King Abdulaziz Univ, Fac Med, Dept Pathol, Rabigh, Saudi Arabia
[2] Umm Al Qura Univ, Coll Med, Dept Pathol, Mecca, Saudi Arabia
[3] Univ Jeddah, Fac Med, Dept Pathol, Jeddah, Saudi Arabia
[4] King Abdulaziz Specialist Hosp, Dept Surg, Taif, Saudi Arabia
[5] King Abdulaziz Univ, Fac Med, Dept Clin Biochem, Jeddah, Saudi Arabia
[6] King Faisal Specialist Hosp & Res Ctr, Dept Neurosci, Jeddah, Saudi Arabia
[7] King Abdulaziz Univ, Fac Med, Dept Internal Med, Jeddah, Saudi Arabia
[8] King Fahad Gen Hosp, Dept Neurosurg, Jeddah, Saudi Arabia
[9] King Abdulaziz Univ, Fac Med, Dept Pediat, Jeddah, Saudi Arabia
关键词
medulloblastoma; cancer stem cells; CD133; CD44; OCT4; prognosis; SELF-RENEWAL; PLURIPOTENT; DIFFERENTIATION; IDENTIFICATION; INHIBITION; IMPACT;
D O I
10.5114/fn.2024.144903
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction: Cancer stem cells (CSCs) are principal drivers in medulloblastoma (MB) initiation, growth, and progression. Our study aimed to explore the expression of CD133, CD44, and OCT4 signaling markers and their effects on the progression of MB. Material and methods: A retrospective cohort analysis was conducted on brain tissue of 24 pediatric cases of MB from 2016-2020. Protein expression levels of CSC markers CD133, CD44, and OCT4 were evaluated immunohistochemically and their correlation with (3-catenin activity was statistically analyzed. Results: The mean age of patients was 10.2 years (range 3-17), with 18 (75%) males and 6 (25%) females. (3-catenin was expressed in 20 (83.3%) tumors, and 4 (16.7%) tumors showed no expression. CD133 was minimally expressed in 6 (25%) tumors and 18 tumors (75%) showed no expression. CD44 was highly expressed in 6 (25%) tumors and 18 (75%) tumors showed minimal to no expression. OCT4 was expressed in all tumors. Despite MBs with positive (3-catenin expression and absent CD133 expression having longer progression-free survival (PFS), this impact on PFS did not reach statistical significance (p = 0.76). However, statistically significant differences in PFS were observed in MBs with positively expressed (3-catenin and minimal or no CD44 expression, which showed prolonged PFS (p = 0.0064). MB patients who did not express CD133 and received combined radiotherapy (RTx) and chemotherapy (CTx) showed longer PFS compared to MB patients with minimal CD133 expression. However, this association was statistically insignificant (p = 0.42). The impact of CD44 expression and chemoradiation on PFS was statistically significant (p = 0.0035). MB patients with absent or minimal CD44 expression who received RTx and CTx showed the longest PFS. Conclusions: Medulloblastomas not expressing CSC markers (CD133, CD44) are associated with prolonged PFS and less resistance to chemoradiation. However, (3-catenin is considered the main predictor for prognosis when compared to CSC markers.
引用
收藏
页码:376 / 385
页数:10
相关论文
共 56 条
[31]   Isolation of neural stem cells from the postnatal cerebellum [J].
Lee, A ;
Kessler, JD ;
Read, TA ;
Kaiser, C ;
Corbeil, D ;
Huttner, WB ;
Johnson, JE ;
Wechsler-Reya, RJ .
NATURE NEUROSCIENCE, 2005, 8 (06) :723-729
[32]   The 2021 WHO Classification of Tumors of the Central Nervous System: a summary [J].
Louis, David N. ;
Perry, Arie ;
Wesseling, Pieter ;
Brat, Daniel J. ;
Cree, Ian A. ;
Figarella-Branger, Dominique ;
Hawkins, Cynthia ;
Ng, H. K. ;
Pfister, Stefan M. ;
Reifenberger, Guido ;
Soffietti, Riccardo ;
von Deimling, Andreas ;
Ellison, David W. .
NEURO-ONCOLOGY, 2021, 23 (08) :1231-1251
[33]   Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells [J].
Lu, Yuhua ;
Zhu, Hui ;
Shan, Haiyan ;
Lu, Junjie ;
Chang, Xu ;
Li, Xiaohong ;
Lu, Jingjing ;
Fan, Xiangjun ;
Zhu, Shajun ;
Wang, Yao ;
Guo, Qingsong ;
Wang, Lei ;
Huang, Yan ;
Zhu, Mingyan ;
Wang, Zhiwei .
CANCER LETTERS, 2013, 340 (01) :113-123
[34]   Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty [J].
Magee, Jeffrey A. ;
Piskounova, Elena ;
Morrison, Sean J. .
CANCER CELL, 2012, 21 (03) :283-296
[35]   Management of Pediatric and Adult Patients with Medulloblastoma [J].
Martin, Allison M. ;
Raabe, Eric ;
Eberhart, Charles ;
Cohen, Kenneth J. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (04) :581-594
[36]   IN-VITRO COLONY FORMATION BY NORMAL AND LEUKEMIC HUMAN HEMATOPOIETIC CELLS - CHARACTERIZATION OF COLONY-FORMING CELLS [J].
MOORE, MAS ;
WILLIAMS, N ;
METCALF, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1973, 50 (03) :603-623
[37]   CD44 in cancer [J].
Naor, D ;
Nedvetzki, S ;
Golan, I ;
Melnik, L ;
Faitelson, Y .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2002, 39 (06) :527-579
[38]   Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4 [J].
Nichols, J ;
Zevnik, B ;
Anastassiadis, K ;
Niwa, H ;
Klewe-Nebenius, D ;
Chambers, I ;
Schöler, H ;
Smith, A .
CELL, 1998, 95 (03) :379-391
[39]   Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy [J].
Okamoto, Koichi ;
Ninomiya, Itasu ;
Ohbatake, Yoshinao ;
Hirose, Atsushi ;
Tsukada, Tomoya ;
Nakanuma, Shinichi ;
Sakai, Seisho ;
Kinoshita, Jun ;
Makino, Isamu ;
Nakamura, Keishi ;
Hayashi, Hironori ;
Oyama, Katsunobu ;
Inokuchi, Masafumi ;
Nakagawara, Hisatoshi ;
Miyashita, Tomoharu ;
Hidehiro, Tajima ;
Takamura, Hiroyuki ;
Fushida, Sachio ;
Ohta, Tetsuo .
ONCOLOGY REPORTS, 2016, 36 (06) :3333-3342
[40]   CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 [J].
Ostrom, Quinn T. ;
Gittleman, Haley ;
Truitt, Gabrielle ;
Boscia, Alexander ;
Kruchko, Carol ;
Barnholtz-Sloan, Jill S. .
NEURO-ONCOLOGY, 2018, 20 :1-86